Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2008-01-22
2008-01-22
Romeo, David (Department: 1649)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C424S009100, C435S007200, C435S007210
Reexamination Certificate
active
07320785
ABSTRACT:
The present invention provides methods and compositions for modulating the phosphorylation of DARPP-32 in a serotonergic receptor intracellular signaling pathway. The invention provides methods and compositions for modulating the activities of DARPP-32, casein kinase 1 (CK1), cyclin-dependent kinase 5 (Cdk5), AMPA receptors, protein phosphatase-1 (PP-1), protein phosphatase 2C (PP2C), protein phosphatase 2B (PP2B) and/or protein phosphatase 2A (PP2A) in cells or tissues. The invention provides methods of treating serotonergic intracellular signaling pathway disorders, e.g., depression. The invention provides methods of treating dopamine-related disorders. The invention provides methods of identifying agents that modulate the activities of serotonergic receptor intracellular signaling molecules, DARPP-32, casein kinase 1, cyclin-dependent kinase 5, AMPA receptors, protein phosphatase-1, protein phosphatase 2C, protein phosphatase 2B and/or protein phosphatase 2A, for use in such treatments. The invention also provides methods of modulating phosphorylation-dependent activation of AMPA receptors for use in such treatments.
REFERENCES:
patent: 5902815 (1999-05-01), Olney et al.
patent: 6166008 (2000-12-01), Johnson et al.
patent: 6410556 (2002-06-01), Andersen et al.
patent: 2002/0042357 (2002-04-01), Hanson et al.
patent: 2002/0103185 (2002-08-01), Sanner et al.
patent: PCT/US02/25455 (2002-12-01), None
Desdouits et al. (Feb. 1998). Dephosphorylation of SER-137 in DARPP-32 by protein phosphatases 2A and 2C: different roles in vitro and in striatonigral neurons. Biochemical Journal, 330, 211-216.
Weintraub et al (2005). MOvement disorders. 20, 1161-1169.
Perilstein et al. (1991). J. Clin Psych. 52, 169-170. Abstract only.
Zajecka et al (1991). J. Clin. Psych. 52, 66-68.Abstract only.
Kafka (1991). Br. J.Psychiatry. 158, 844-847.Abstract only.
Lorifice (1991). J. Clin. Psych. 52, 41 (abstract only).
Bianchi (1990). Am. J. Psych. (abstract only).
Ferguson et al. (1999). Int. J. Eating Disord. 25, 11-17.
Gigli et al (1994). Seizure. 3, 221-224. (abstract only).
Grabowski et al (1995) J. Clin Psychopharm. 15, 163-164. (abstract only).
Mei lai et al (2005). Microbiology. 151, 1159-1167.
Barnes et al., “A Review of Central 5-HT Receptors and Their Function,” (1999), Neuropharmacology, 38:1083-1152.
Barria et al., “Regulatory Phosphorylation of AMPA-Type Glutamate Receptors by CaM-KII During Long-Term Potentiation,” (1997), Science, 276:2042-2045.
Beasley et al., “Fluoxetine: A Review of Receptor and Functional Effects and Their Clinical Implications,” (1992), Psychopharmacology, 107:1-10.
Bibb et al., “Phosphorylation of DARPP-32 By Cdk5 Modulates Dopamine Signaling In Neurons,” (1999), Nature 402: 669-671.
Bristow et al., “Evidence For Accelerated Desenstitisation of 5-HT2cReceptors Following Combined Treatment with Fluoxetine and the 5-HT1aReceptor Antagonist, WAY 100,635 In The Rat,” (2000), Neuropharmacology, 39:1222-1236.
Desdouits et al., “Dephosphorylation of Ser-137 in DARPP-32 By Protein Phosphatases 2A and 2C: Different rolesin vitroand in Striatonigral Neurons,” (1998), J. Biochem, 330:211-216.
Desdouits et al., “Dopamine- and cAMP-Regulated Phosphoprotein DARPP-32: Phosphorylation of Ser-137 By Casein Kinase I Inhibits Dephosphorylation of Thr-34 By Calcineurin,” (1995), PNAS, 92:2682-2685.
Desdouits et al., “Phosphorylation of DARPP-32, a Dopamine- and cAMP-regulated Phosphoprotein, by Casein Kinase Iin Vitro, andin Vivo,” (1995), The Journal of Biological Chemistry, 270:8772-8778.
Duman et al., “A Molecular and Cellular Theory of Depression,” (1997), Arch Gen Psychiatry, 54:597-606.
Fienberg et al., “DARPP-32: Regulator of the Efficacy of Dopaminergic Neurotransmission,” (1998), Science, 281:838-842.
Fleischhacker et al., “A Multicenter Double-Blind Study of Three Different Doses of the New cAMP-Phosphodiesterase Inhibitor Rolipram In Patients With Major Depressive Disorder,” (1992), Neuropsychobiology, 26:59-64.
Fukunaga et al., “Dephosphorylation of Autophosphorylated Ca2+/ Calmodulin-Dependent Protein Kinase II by Protein Phosphatase,” (1993), The Journal of Biological Chemistry, 268:133-137.
Greengard et al., “Beyond the Dopamine Receptor: The DARPP-32/Protein Phosphatase-1 Cascade,” (1999), Nature, 23:435-447.
Greengard et al., “Enhancement of the Glutamate Response by cAMP-Dependent Protein Kinase in Hippocampal Neurons,” (1991), Science, 253:1135-1138.
Greengard et al., “The Neurobiology of Slow Synaptic Transmission,” (2001), Science, 294:1024-1030.
Gross et al., “Casein Kinase I: Spatial Organization and Positioning of a Multifunctional Protein Kinase Family,” (1998), Cell Signal, 10:699-711.
Guitart et al., “Chronic Administration of Lithium or Other Antidepressants Increases Levels of DARPP-32 in Rat Frontal Cortex,” (1992), Journal of Neurochemistry, 59:1164-1167.
Hanada et al., “Regulation of the TAKI Signaling Pathway by Protein Phosphatase 2C,” (2001), The Journal of Biological Chemistry, 276:5753-5759.
Hemmings et al., “DARPP-32 A Dopamine- and Adenosine 3′:5′-Monophospate-Regulated Phosphoprotein:Regional, Tissue, and Phylogenetic Distribution,” (1986), The Journal of Neuroscience, 6:1469-1481.
Hemmings, et al., “DARPP-32, A Dopamine-Regulated Neuronal Phosphoprotein, Is A Potent Inhibitor Of Protein Phosphatase-1,” (1998), Nature, 310:503-508.
Hishiya et al., “Protein Phosphatase 2C Inactivates F-Actin Binding of Human Platelet Meosin,” (1999), The Journal of Biological Chemistry, 274:26705-26712.
Horowski et al., “Clinical Effects of the Neurotropic Selective cAMP Phosphodiestersase Inhibitor Rolipram In Depressed Patients: Global Evaluation of the Preliminary Reports,” (1985), current Therapeutic Research, 38:23-29.
Ivkovic et al., “Brain-Derived Neurotrophic Factor Regulates Maturation of the DARPP-32 Phenotype In Striatal Medium Spiny Neurons: StudiesIN VIVOandIN VITRO,” (1997), Neuroscience, 79:509-516.
Kusakawa et al., “Calpain-Dependent Proteolytic Cleavage of the p35 Cyclin Dependent Kinase 5 Activator to p25,” (2000), The Journal of Biological Chemistry 275:17166-17172.
Lee et al., “Neurotoxicity Induces Cleavage of p35 to p25 By Calpin,” (2000), Nature, 405:360-364.
Li et al., “Antidepressant-Like Actions of an AMPA Receptor Potentiator (LY392098),” (2001) Neuropharmacology, 40:1028-1033.
Liu et al., “Regulation Of Cyclin-Dependent Kinase 5 and Casein Kinase 1 By Metabotropic Glutamate Receptors,” (2001), PNAS, 98:11062-11068.
Manji et al., “The Cellular Neurobiology of Depression,” (2001), Nature Medicine, 7:541-547.
Marley et al., “The Cloning Expression And Tissue Distribution of Human PP2cβ,” (1998), FEBS Letters, 431:121-124.
Moine et al., “D1 and D2 Dopamine Receptor Gene Expression in the Rat Striatum: Sensitive cRNA Probes Demonstrate Prominent Segregation of D1 and D2 mRNA's in District Neuronal Populations of the Dorsal and Ventral Striatum,” (1995), The Journal of Comparative Neurology, 355:418-426.
Murphy et al., “Brain Serotonin Neurotransmission: An Overview and Update With an Emphasis on Serotonin Subsystem Heterogeneity, Multiple Receptors, Interactions With Other Neurotransmitter Systems, and Consequent Implications For Understanding the Actions of Serotonergic Drugs,” (1998), J. Clin. Psychiatry, 59(Suppl 15):4-12.
Nath et al., “Processing of cdk5 Activator p35 To Its Truncated Form (p25) By Calpain In Acutely Injured Neuronal Cells,” (2000), Biochemical and Biophysical Research Communications, 274:16-21.
Nishi et al., “Bidirectional Regulation of DARPP-32 Phosphorylation By Dopamine,” (1997), The Journal of Neuroscience, 17:8147-8155.
Ouimet et al., &#x
Greengard Paul
Rakhilin Sergey V.
Starkova Natalia
Svenningsson Per
Hoxie & Associates LLC
Romeo David
Standley Steven
The Rockefeller University
LandOfFree
Compositions and methods for modulation of DARPP-32... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for modulation of DARPP-32..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for modulation of DARPP-32... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2800069